179 related articles for article (PubMed ID: 38391053)
1. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer.
Li S; Wang S; Zhang A; Luo L; Song J; Wei G; Fang Z
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391053
[TBL] [Abstract][Full Text] [Related]
2. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
[No Abstract] [Full Text] [Related]
3. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
4. Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy.
Ma X; Yang S; Zhang T; Wang S; Yang Q; Xiao Y; Shi X; Xue P; Kang Y; Liu G; Sun ZJ; Xu Z
Acta Pharm Sin B; 2022 Jan; 12(1):451-466. PubMed ID: 35127398
[TBL] [Abstract][Full Text] [Related]
5. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
8. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells.
Jafari S; Lavasanifar A; Hejazi MS; Maleki-Dizaji N; Mesgari M; Molavi O
Daru; 2020 Jun; 28(1):159-169. PubMed ID: 31942696
[TBL] [Abstract][Full Text] [Related]
9. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
10. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
11. Photothermal MnO
Chen Z; Zhang Q; Huang Q; Liu Z; Zeng L; Zhang L; Chen X; Song H; Zhang J
Int J Pharm; 2022 Apr; 617():121578. PubMed ID: 35176333
[TBL] [Abstract][Full Text] [Related]
12. Transformable prodrug nanoplatform
Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
[No Abstract] [Full Text] [Related]
13. Ferritin Nanocaged Doxorubicin Potentiates Chemo-Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death.
Chen Y; Zeng L; Zhu H; Wu Q; Liu R; Liang Q; Chen B; Dai H; Tang K; Liao C; Huang Y; Yan X; Fan K; Du JZ; Lin R; Wang J
Small Methods; 2023 May; 7(5):e2201086. PubMed ID: 36446639
[TBL] [Abstract][Full Text] [Related]
14. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy.
Jin C; Wang Y; Li Y; Li J; Zhou S; Yu J; Wang Z; Yu Y; Zhang H; Wang D; He Z; Wang Y
Int J Pharm; 2021 Sep; 607():121027. PubMed ID: 34418473
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors.
Yerragopu AK; Vellapandian C
J Biochem Mol Toxicol; 2023 May; 37(5):e23327. PubMed ID: 36807623
[TBL] [Abstract][Full Text] [Related]
17. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin IIa induces caspase-3-dependent apoptosis and enhances autophagy in lipopolysaccharide-stimulated RAW 264.7 macrophages.
He J; Wang Y; Xu LH; Qiao J; Ouyang DY; He XH
Int Immunopharmacol; 2013 May; 16(1):27-34. PubMed ID: 23541744
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Immunogenic Cell Death and Antigen Presentation
He T; Wang L; Gou S; Lu L; Liu G; Wang K; Yang Y; Duan Q; Geng W; Zhao P; Luo Z; Cai K
ACS Nano; 2023 Jun; 17(11):9953-9971. PubMed ID: 37212750
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
Dong H; Gao M; Lu L; Gui R; Fu Y
Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
